Quest PharmaTech, Inc.
Quest PharmaTech, Inc. is a biotechnology company, which engages in development and commercialization of oncology product candidates. It develops a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants and photodynamic therapy. The company's technology platform includes a series of monoclonal antibodies that target several different cancer markers such as CA125, MUC1, PSA, CA19.9 and TAG72. It's most advanced of its product candidates is Oregovomab, an anti-CA125 monoclonal antibody, in combination with front-line chemotherapy for the treatment of advanced ovarian cancer. The company's technologies include Chemo Enhanced Immuno-Therapy, Combination Therapy and SonoLight Technology. Quest PharmaTech was founded in 1996 and is headquartered in Edmonton, Canada.